Campbell & Co Investment Adviser’s Aurinia Pharmaceuticals AUPH Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,675	Closed	-$330K	–	1065
2025 Q4	$330K	Sell	20,675 -9,504	-31%	-$135K	0.02%	954
2025 Q3	$333K	Sell	30,179 -9,586	-24%	-$105K	0.03%	876
2025 Q2	$337K	Sell	39,765 -4,307	-10%	-$34.5K	0.02%	917
2025 Q1	$354K	Buy	+44,072	New	+$357K	0.03%	802
2024 Q3	–	Sell	-19,597	Closed	-$112K	–	1083
2024 Q2	$112K	Sell	19,597 -217,498	-92%	-$1.15M	0.01%	999
2024 Q1	$1.19M	Buy	237,095 +4,684	+2%	+$31.8K	0.1%	323
2023 Q4	$2.09M	Buy	+232,411	New	+$1.91M	0.19%	121

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Campbell & Co Investment Adviser's AUPH Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2026, closing a stake of 20,675 shares — an estimated $330K sold.

Campbell & Co Investment Adviser first reported a position in AUPH in Q4 2023 and held it in 7 quarters. The position peaked at $2.09M in Q4 2023. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Campbell & Co Investment Adviser reported no remaining Aurinia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 20,675 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $330K.
Campbell & Co Investment Adviser first reported a position in Aurinia Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Campbell & Co Investment Adviser's Aurinia Pharmaceuticals position peaked at $2.09M in Q4 2023.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.